Search

Outcomes of treat & extend ranibizumab in diabetic macular oedema

This study retrospectively evaluated 118 eyes of 87 patients who received ranibizumab in a treat and extend regimen for diabetic macular oedema (DMO). Data were collected for patients under follow-up for 24 months. After 24 months, patients gained a mean...

Two-year interim safety results of the 0.2ug/day FAC intravitreal implant for the treatment of DMO

This is a 24-month interim prospective observational study of 95 previously steroid challenged patients (115 eyes) receiving intravitreal 0.2ug/day fluocinolone acetaid (FAC) implant for diabetic macular oedema (DMO) treatment. The mean IOP for pre- and post- FAC implants were stable,...

Cystoid macular oedema following retinal detachment surgery

There are limited studies examining the incidence and risk factors for postoperative cystoid macular oedema (CMO) following rhegmatogenous retinal detachment (RRD) repair. Postoperative CMO is thought to be due to pro-inflammatory state, where numerous cytokines lead to tight junction dysfunction,...

Foveal displacement after macular hole surgery

Previous studies show that internal limiting membrane (ILM) peeling during macular hole surgery is associated with retinal shrinkage (microtubule depolymerization of the axons of the inner retina) and nasal shift of the fovea. A temporal inverted ILM flap technique was...

Evaluation of fluocinolone acetonide in the management of BRC

This is a single-centre, retrospective, intervention study of 15 eyes of birdshot retinochoroiditis (BRC) patients who received Iluvein, with a mean follow-up period of 31 months. Five eyes had previously received dexamethasone intravitreal implant 0.7mg (Ozurdex). Fluorescein angiography (FA) showed...

Bromfenac versus betamethasone in diabetic macular oedema

This is a randomised, prospective, single-centre trial in patients diagnosed with diabetic macular oedema (DMO) with central subfield thickness (CST) of 250-500µm, who refused anti-VEGF treatment. Nineteen eyes of 19 patients were randomised to bromfenac (BF) or betamethasone (BM) drops,...

The compendium to clinical evidence in DMO treatment

This review article summarises the current evidence base in the treatment options for diabetic macular oedema (DMO). The authors have included many real-world data studies that provided valuable insights into the optimal management of DMO. The authors argue that these...

Comprehensive review of inherited retinal diseases

The authors offer an up-to-date review of inherited retinal diseases (IRDs). In each section the authors discuss the molecular basis of disease, genotype and clinical manifestation. They also discuss the investigation findings and current evidence in the treatment of the...

Long-term treatment for diabetic macular oedema

The authors set out to characterise anti-VEGF treatment patterns and long-term outcomes in patients with diabetic macular oedema. A retrospective analysis of over 190 thousand patients on the Intelligent Research in Sight registry was performed. Of these, 1236 eyes have...